Works matching IS 00302414 AND DT 2009 AND VI 77 AND IP 2
Results: 10
Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 75, doi. 10.1159/000226772
- By:
- Publication type:
- Article
How Can Second-Line Therapy for Metastatic Renal Cell Carcinoma Help to Define an Overall Management Strategy?
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 82, doi. 10.1159/000228835
- By:
- Publication type:
- Article
Decorin Suppresses Bone Metastasis in a Breast Cancer Cell Line.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 92, doi. 10.1159/000228253
- By:
- Publication type:
- Article
Clinical Characteristics and Outcomes of Lung Cancer with Pulmonary Embolism.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 100, doi. 10.1159/000229503
- By:
- Publication type:
- Article
Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 107, doi. 10.1159/000229504
- By:
- Publication type:
- Article
Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 113, doi. 10.1159/000229787
- By:
- Publication type:
- Article
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 120, doi. 10.1159/000229751
- By:
- Publication type:
- Article
Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 124, doi. 10.1159/000229752
- By:
- Publication type:
- Article
Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 134, doi. 10.1159/000229753
- By:
- Publication type:
- Article
Limited Value of CA 19-9 in Predicting Early Treatment Failure in Patients with Advanced Pancreatic Cancer.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 140, doi. 10.1159/000229754
- By:
- Publication type:
- Article